%0 Journal Article
%A Kleineberg, Nina N.
%A Knauss, Samuel
%A Gülke, Eileen
%A Pinnschmidt, Hans O.
%A Jakob, Carolin E. M.
%A Lingor, Paul
%A Hellwig, Kerstin
%A Berthele, Achim
%A Höglinger, Günter
%A Fink, Gereon R.
%A Endres, Matthias
%A Gerloff, Christian
%A Klein, Christine
%A Stecher, Melanie
%A Classen, Annika Y.
%A Rieg, Siegbert
%A Borgmann, Stefan
%A Hanses, Frank
%A Rüthrich, Maria M.
%A Hower, Martin
%A Tometten, Lukas
%A Haselberger, Martina
%A Piepel, Christiane
%A Merle, Uta
%A Dolff, Sebastian
%A Degenhardt, Christian
%A Jensen, Björn-Erik O.
%A Vehreschild, Maria J. G. T.
%A Erber, Johanna
%A Franke, Christiana
%A Warnke, Clemens
%T Neurological symptoms and complications in predominantly hospitalized COVID‐19 patients: Results of the European multinational Lean European Open Survey on SARS‐Infected Patients (LEOSS)
%J European journal of neurology
%V 28
%N 12
%@ 1351-5101
%C Oxford
%I Blackwell Science
%M FZJ-2021-03869
%P 3925-3937
%D 2021
%X Background and purposeDuring acute coronavirus disease 2019 (COVID-19) infection, neurological signs, symptoms and complications occur. We aimed to assess their clinical relevance by evaluating real-world data from a multinational registry.MethodsWe analyzed COVID-19 patients from 127 centers, diagnosed between January 2020 and February 2021, and registered in the European multinational LEOSS (Lean European Open Survey on SARS-Infected Patients) registry. The effects of prior neurological diseases and the effect of neurological symptoms on outcome were studied using multivariate logistic regression.ResultsA total of 6537 COVID-19 patients (97.7% PCR-confirmed) were analyzed, of whom 92.1% were hospitalized and 14.7% died. Commonly, excessive tiredness (28.0%), headache (18.5%), nausea/emesis (16.6%), muscular weakness (17.0%), impaired sense of smell (9.0%) and taste (12.8%), and delirium (6.7%) were reported. In patients with a complicated or critical disease course (53%) the most frequent neurological complications were ischemic stroke (1.0%) and intracerebral bleeding (ICB; 2.2%). ICB peaked in the critical disease phase (5%) and was associated with the administration of anticoagulation and extracorporeal membrane oxygenation (ECMO). Excessive tiredness (odds ratio [OR] 1.42, 95% confidence interval [CI] 1.20–1.68) and prior neurodegenerative diseases (OR 1.32, 95% CI 1.07–1.63) were associated with an increased risk of an unfavorable outcome. Prior cerebrovascular and neuroimmunological diseases were not associated with an unfavorable short-term outcome of COVID-19.ConclusionOur data on mostly hospitalized COVID-19 patients show that excessive tiredness or prior neurodegenerative disease at first presentation increase the risk of an unfavorable short-term outcome. ICB in critical COVID-19 was associated with therapeutic interventions, such as anticoagulation and ECMO, and thus may be an indirect complication of a life-threatening systemic viral infection.
%F PUB:(DE-HGF)16
%9 Journal Article
%$ 34411383
%U <Go to ISI:>//WOS:000692461300001
%R 10.1111/ene.15072
%U https://juser.fz-juelich.de/record/901854